The putative role of isoprostanes in human cardiovascular physiology and disease: Following the fingerprints

Heart

Volumn 89, Issue 8, 2003, Pages 821-822

  Cracowski, Jean Luc ^a  

^a UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6,8 DIFLUORO 1,2,3,4 TETRAHYDRO 9 (4 METHYLSULFONYLBENZYL)CARBAZOLE 1 ACETIC ACID; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CYCLOOXYGENASE 2 INHIBITOR; ENDOTHELIN 1; HYDROXYICOSATETRAENOIC ACID; ISOPROSTANE; PHOSPHOLIPID; PROSTAGLANDIN; S 18886; THROMBOXANE A2; THROMBOXANE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; HEART FAILURE; HUMAN; LIPID PEROXIDATION; MITOGENESIS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; VASOCONSTRICTION;

EID: 0041666591     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.89.8.821     Document Type: Review

References (17)

1. 2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000;28:505-13.
2. 2-isoprostanes) in smokers. N Engl J Med 1995;332:1198-203.
3. Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci 2002;23:360-6.
4. 2α in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 1998;97:1536-9.
5. Li H, Lawson JA, Reilly M, et al. Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine. Proc Natl Acad Sci USA 1999;96:13381-6.
6. 2-isoprostanes in patients with severe heart failure. Heart 2000;84:439-40.
7. 21-isoprostane concentrations in patients with non-ischaemic congestive heart failure: a marker of oxidative stress. Heart 2003;89:871-4.
8. Belhassen L, Pelle G, Sediame S, et al. Improvement of endothelial function by TP-receptor antagonist S18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol (in press).
9. Cayatte AJ, Du Y, Oliver-Krasinski J, et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:1724-8.
10. Pratico D, Tangirala RK, Rader DJ, et al. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med 1998;4:1189-92.
11. Jankov RP, Belcastro R, Ovcina E, et al. Thromboxane A(2) receptors mediate pulmonary hypertension in 60% oxygen-exposed newborn rats by a cyclooxygenase-independent mechanism. Am J Respir Crit Care Med 2002;166:208-14.
12. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119:39S-63S.
13. Kinsella BT. Thromboxane A2 signalling in humans: a 'tail' of two receptors. Biochem Soc Trans 2001;29:641-54.
14. 2) evoked contractions in human internal mammary artery. Life Sci 2001;68:2405-13.
15. 2-isoprostanes possess no vasomotor effects in the rat thoracic aorta, the human internal mammary artery and the human saphenous vein. Br J Pharmacol 2002;135:1276-80.
16. Janssen U, Tazzeo T. Involvement of TP and EP3 receptors in vasoconstrictor responses to isoprostanes in pulmonary vasculature. J Pharmacol Exp Ther 2002;301:1060-6.
17. Morrow JD, Awad JA, Wu A, et al. Nonenzymatic free radical-catalyzed generation of thromboxane-like compounds (isothromboxanes) in vivo. J Biol Chem 1996;271:23185-90.